(CTKB) Cytek Biosciences - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NASDAQ (USA) | Currency USD | Market Cap: 576m | Total Return 9.7% in 12m

Stock: Cell Analyzers, Cell Sorters, Reagents, Software

Total Rating 34
Risk 78
Buy Signal -0.45
Medical Devices +1.0
Health Care Equipment +2.6
Market Cap: 576m
Avg Trading Vol: 3.51M USD
ATR: 4.63%
Peers RS (IBD): 56.0
Risk 5d forecast
Volatility 66.6%
Relative Tail Risk -14.2%
Reward TTM
Sharpe Ratio 0.41
Alpha -9.55
Character TTM
Beta 1.205
Beta Downside 2.040
Drawdowns 3y
Max DD 79.82%
CAGR/Max DD -0.24

EPS (Earnings per Share)

EPS (Earnings per Share) of CTKB over the last years for every Quarter: "2021-03": 0, "2021-06": 0.07, "2021-09": 0.02, "2021-12": 0.03, "2022-03": 0.01, "2022-06": 0.03, "2022-09": 0.04, "2022-12": 0.06, "2023-03": -0.05, "2023-06": -0.03, "2023-09": -0.05, "2023-12": 0.04, "2024-03": -0.05, "2024-06": -0.08, "2024-09": 0.01, "2024-12": 0.1208, "2025-03": -0.0272, "2025-06": -0.04, "2025-09": -0.04, "2025-12": -0.2872,
EPS CAGR: -68.41%
EPS Trend: -46.2%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of CTKB over the last years for every Quarter: 2021-03: 24.272, 2021-06: 30.408, 2021-09: 34.376, 2021-12: 38.894, 2022-03: 35.064, 2022-06: 40.159, 2022-09: 40.477, 2022-12: 48.336, 2023-03: 37.088, 2023-06: 49.693, 2023-09: 48, 2023-12: 58.233, 2024-03: 44.86, 2024-06: 46.617, 2024-09: 51.5, 2024-12: 57.476, 2025-03: 41.457, 2025-06: 45.602, 2025-09: 52.293, 2025-12: 62.141,
Rev. CAGR: 16.49%
Rev. Trend: 64.1%
Last SUE: 3.15
Qual. Beats: 1

Description: CTKB Cytek Biosciences March 04, 2026

Cytek Biosciences, Inc. (CTKB) develops and sells cell analysis tools for biomedical research and clinical applications. The companys product portfolio includes aurora and northern lights systems, cell sorters, imaging flow cytometers, and reagent preparation systems. These instruments are used for cell analysis, a critical component in drug discovery and disease diagnostics.

CTKB also provides reagents, kits, and software for its instruments, along with automated sample loading systems. Its business model involves selling both capital equipment and recurring consumables. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The life sciences tools and services sector, where CTKB operates, is characterized by ongoing innovation in analytical technologies.

Distribution occurs through direct sales forces in major markets like North America, Europe, China, and Asia-Pacific, and via distributors in other regions. Further research into CTKBs financial performance and market position can be found on ValueRay.

Headlines to watch out for

  • Research and clinical demand for cell analysis tools drives revenue
  • New product launches expand market share and customer base
  • Global economic conditions impact research funding and capital expenditures
  • Regulatory approvals for new instruments affect market entry
  • Competition from established and emerging cell analysis providers impacts sales

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income: -66.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.02 > 0.02 and ΔFCF/TA -6.27 > 1.0
NWC/Revenue: 155.9% < 20% (prev 164.0%; Δ -8.09% < -1%)
CFO/TA -0.01 > 3% & CFO -4.69m > Net Income -66.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.04 > 1.5 & < 3
Outstanding Shares: last quarter (128.2m) vs 12m ago -0.80% < -2%
Gross Margin: 51.84% > 18% (prev 0.55%; Δ 5.13k% > 0.5%)
Asset Turnover: 41.93% > 50% (prev 40.13%; Δ 1.80% > 0%)
Interest Coverage Ratio: -14.51 > 6 (EBITDA TTM -15.9m / Interest Expense TTM 1.92m)

Altman Z'' 2.49

A: 0.68 (Total Current Assets 392.0m - Total Current Liabilities 77.8m) / Total Assets 461.5m
B: -0.22 (Retained Earnings -101.7m / Total Assets 461.5m)
C: -0.06 (EBIT TTM -27.9m / Avg Total Assets 480.5m)
D: -0.83 (Book Value of Equity -99.4m / Total Liabilities 119.8m)
Altman-Z'' Score: 2.49 = A

Beneish M -3.19

DSRI: 1.18 (Receivables 72.1m/60.6m, Revenue 201.5m/200.5m)
GMI: 1.07 (GM 51.84% / 55.43%)
AQI: 0.58 (AQ_t 0.09 / AQ_t-1 0.15)
SGI: 1.01 (Revenue 201.5m / 200.5m)
TATA: -0.13 (NI -66.5m - CFO -4.69m) / TA 461.5m)
Beneish M-Score: -3.19 (Cap -4..+1) = AA

What is the price of CTKB shares?

As of March 25, 2026, the stock is trading at USD 4.63 with a total of 807,267 shares traded.
Over the past week, the price has changed by +8.94%, over one month by +6.19%, over three months by -8.68% and over the past year by +9.72%.

Is CTKB a buy, sell or hold?

Cytek Biosciences has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold CTKB.
  • StrongBuy: 1
  • Buy: 1
  • Hold: 3
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the CTKB price?

Issuer Target Up/Down from current
Wallstreet Target Price 6 29.6%
Analysts Target Price 6 29.6%

CTKB Fundamental Data Overview March 23, 2026

P/E Forward = 370.3704
P/S = 2.8582
P/B = 1.6909
Revenue TTM = 201.5m USD
EBIT TTM = -27.9m USD
EBITDA TTM = -15.9m USD
Long Term Debt = 525k USD (from longTermDebt, last quarter)
Short Term Debt = 11.7m USD (from shortTermDebt, last quarter)
Debt = 33.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.8m USD (from netDebt column, last quarter)
Enterprise Value = 347.4m USD (575.9m + Debt 33.0m - CCE 261.5m)
Interest Coverage Ratio = -14.51 (Ebit TTM -27.9m / Interest Expense TTM 1.92m)
EV/FCF = -39.61x (Enterprise Value 347.4m / FCF TTM -8.77m)
FCF Yield = -2.52% (FCF TTM -8.77m / Enterprise Value 347.4m)
FCF Margin = -4.35% (FCF TTM -8.77m / Revenue TTM 201.5m)
Net Margin = -33.02% (Net Income TTM -66.5m / Revenue TTM 201.5m)
Gross Margin = 51.84% ((Revenue TTM 201.5m - Cost of Revenue TTM 97.0m) / Revenue TTM)
Gross Margin QoQ = 52.92% (prev 52.69%)
Tobins Q-Ratio = 0.75 (Enterprise Value 347.4m / Total Assets 461.5m)
Interest Expense / Debt = 2.20% (Interest Expense 725k / Debt 33.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -22.1m (EBIT -27.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.04 (Total Current Assets 392.0m / Total Current Liabilities 77.8m)
Debt / Equity = 0.10 (Debt 33.0m / totalStockholderEquity, last quarter 341.7m)
Debt / EBITDA = 3.63 (negative EBITDA) (Net Debt -57.8m / EBITDA -15.9m)
Debt / FCF = 6.59 (negative FCF - burning cash) (Net Debt -57.8m / FCF TTM -8.77m)
Total Stockholder Equity = 369.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.85% (Net Income -66.5m / Total Assets 461.5m)
RoE = -18.01% (Net Income TTM -66.5m / Total Stockholder Equity 369.4m)
RoCE = -7.55% (EBIT -27.9m / Capital Employed (Equity 369.4m + L.T.Debt 525k))
RoIC = -5.87% (negative operating profit) (NOPAT -22.1m / Invested Capital 375.9m)
WACC = 9.76% (E(575.9m)/V(608.9m) * Re(10.22%) + D(33.0m)/V(608.9m) * Rd(2.20%) * (1-Tc(0.21)))
Discount Rate = 10.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.98%
[DCF] Fair Price = unknown (Cash Flow -8.77m)
EPS Correlation: -46.22 | EPS CAGR: -68.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 64.12 | Revenue CAGR: 16.49% | SUE: 3.15 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-0.04 | Chg7d=-0.025 | Chg30d=-0.025 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=-0.09 | Chg7d=-0.070 | Chg30d=-0.070 | Revisions Net=+0 | Growth EPS=+72.9% | Growth Revenue=+3.4%
EPS next Year (2027-12-31): EPS=0.04 | Chg7d=-0.020 | Chg30d=-0.020 | Revisions Net=-1 | Growth EPS=+152.9% | Growth Revenue=+7.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)

Additional Sources for CTKB Stock

Fund Manager Positions: Dataroma | Stockcircle